In This Article:
TORONTO and HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced the voting results from the Company’s annual meeting of shareholders held today, September 26, 2024 (the “Meeting”).
Medicenna is pleased to announce that all nominees listed in the management information circular dated August 14, 2024 (the “Circular”), were elected as directors. The results of the vote are detailed below:
|
| Nominee | Votes For | % of Votes For | Votes Against | % of Votes Against | ||||
|
| Dr. Fahar Merchant | 26,237,107 |
| 99.44% |
| 148,557 |
| 0.56% |
|
|
| Mr. Albert Beraldo | 26,325,950 |
| 99.77% |
| 59,714 |
| 0.23% |
|
|
| Dr. John (Jack) Geltosky | 26,190,452 |
| 99.26% |
| 195,212 |
| 0.74% |
|
|
| Ms. Karen Dawes | 26,228,732 |
| 99.41% |
| 156,932 |
| 0.59% |
|
|
| Dr. John H. Sampson | 20,428,706 |
| 77.42% |
| 5,956,958 |
| 22.58% |
|
|
| Mr. Karim Lalji | 26,314,082 |
| 99.73% |
| 71,582 |
| 0.27% |
|
Medicenna shareholders also voted for the appointment of MNP LLP as auditor of the Company.
A total of 45.89% of the issued and outstanding common shares of the Company were represented in person and by proxy at the Meeting.
Please refer to the Circular available on SEDAR+ at www.sedarplus.ca for more information on the business transacted at the Meeting. A report on voting results will also be filed on SEDAR+.
About Medicenna Therapeutics
Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna’s IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials enrolling over 130 patients, including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively. Medicenna’s early-stage high-affinity IL-2β biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Medicenna’s early-stage BiSKITs™ (Bifunctional SuperKine ImmunoTherapies) and the T-MASK™ (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically “cold” tumors.